RxDoctor Payments Data

Chansamorn Nouansavane, MD

Family Medicine · Fort Smith, ARNPI 1811098403

Payments from drug & device makers

$4,182in general payments, 2019–2025

Across 237 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$636
  • Pfizer$231
  • Biohaven Pharmaceutical Holding Company Ltd.$187
  • Amgen$167
  • Lilly USA, LLC$134
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$4,182100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,182 in reported general payments places this provider in the 80th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$37,552
Medicare patients
154
Services billed
883

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide78$86,771
EliquisApixaban76$64,636
OzempicSemaglutide28$26,219
Nurtec OdtRimegepant Sulfate19$22,892
EntrestoSacubitril/Valsartan16$22,539
TrulicityDulaglutide20$20,614
XareltoRivaroxaban21$19,855
JardianceEmpagliflozin17$17,170
FarxigaDapagliflozin Propanediol25$16,497
Breo ElliptaFluticasone/Vilanterol25$12,863
Combivent RespimatIpratropium/Albuterol Sulfate18$8,660
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,358
LinzessLinaclotide13$6,712
Fluticasone-SalmeterolFluticasone Propion/Salmeterol33$6,517
Albuterol Sulfate HfaAlbuterol Sulfate194$5,590

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$134$107,38598 claims
PfizerEliquis, Nurtec Odt, Premarin$231$92,667111 claims
Novo NordiskOzempic$125$26,21928 claims
Boehringer IngelheimJardiance, Combivent Respimat$80$25,82935 claims
NovartisEntresto$56$22,53916 claims
AstraZenecaFarxiga, Symbicort$636$21,06039 claims
GSKBreo Ellipta, Trelegy Ellipta$108$20,22136 claims
AbbVieLinzess$1,310$6,71213 claims
Sanofi-aventis U.S. LLCLantus$12$2,01417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Fort Smith

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →